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Summary
A challenge for the development of therapies selectively targeting leukemic stem cells in acute myeloid leukemia (AML) is
their similarity to normal hematopoietic stem cells (HSCs). Here we demonstrate that the leukemia-propagating cell in mu-
rine CALM/AF10-positive AML differs from normal HSCs by B220 surface expression and immunoglobulin heavy chain rear-
rangement. Furthermore, depletion of B220+ cells in leukemic transplants impaired development of leukemia in recipients.
As in the murine model, human CALM/AF10-positive AML was characterized by CD45RA (B220)-positive, IG DH-JH rear-
ranged leukemic cells. These data demonstrate in a murine leukemia model that AML can be propagated by a transformed
progenitor with lymphoid characteristics, which can be targeted by antibodies that do not crossreact with normal HSCs.Introduction
For most cancers, the cell that propagates tumor growth and is
thought to play a key role in recurrence of disease is unknown.
The study of normal and malignant hematopoiesis has formed
a roadmap for the detailed analysis of the concept of the tu-
mor-initiating cell and has demonstrated that, in leukemia, the
malignant clone is organized in a hierarchy in which only a small
subpopulation of cells—the leukemic stem cells (LSCs)—are
able to initiate and propagate the disease (Hope et al., 2004).
In AML most studies indicate that malignant transformation tar-
gets cells within the hematopoietic stem cell compartment.
However, more recent data demonstrated that multipotentialCANCER CELL 10, 363–374, NOVEMBER 2006 ª2006 ELSEVIER INC. Dprogenitors or more committed myeloid progenitors can also ac-
quire leukemic stem cell properties when transformed by appro-
priate oncogenes (Cozzio et al., 2003; So et al., 2003). These re-
ports clearly demonstrated that cells other than hematopoietic
stem cells can be the target of fully transforming oncogenes,
which are characterized by their ability to transfer self-renewal
potential to committed stages of differentiation (Huntly et al.,
2004; Jamieson et al., 2004). The identification of leukemic
stem cell properties is a key step for an improved understanding
of the biology of acute leukemias and might also have clinical im-
plications: because of its essential role for the initiation and
maintenance of the leukemic clone, a curative therapeutic strat-
egy should be able to eradicate the LSC in the diseased patients.S I G N I F I C A N C E
The identification of tumor stem cells is one of the major goals of cancer research. We report on a murine model demonstrating that
myeloid malignancies such as acute myeloid leukemia can be propagated by a transformed progenitor with lymphoid characteris-
tics. These data extend our previous knowledge about leukemia stem cell candidates in acute leukemia and indicate that leukemia-
propagating cells in AML might differ from the myeloid blast population as well as from the normal hematopoietic stem cell in their
surface antigen profile. These findings suggest that such leukemic stem cell candidates can be targeted with antibodies that spare
the normal stem cell pool. This may pave the way for innovative antibody-based therapeutic strategies in this disease.OI 10.1016/j.ccr.2006.08.023 363
A R T I C L EAt the same time, such a strategy should spare normal hemato-
poietic stem cells (HSCs) to avoid intolerable therapy-associ-
ated stem cell toxicity. However, the major challenge for the de-
velopment of such therapeutic approaches is the often striking
similarity between leukemic and normal HSC, e.g., with regard
to their cell surface markers (Reya et al., 2001; Warner et al.,
2004). The limitations of the therapeutic tools available today
are well known: although standard chemotherapy is highly effec-
tive in inducing remissions in patients with AML, the majority of
patients finally relapse and succumb to this disease (Hiddemann
et al., 2005). One of the reasons for treatment failure is that even
dose-intensive conventional chemotherapy is not able to effi-
ciently target the LSC, demonstrated, for example, by the obser-
vation that patients in morphological complete remission harbor
CD34+/CD382 progenitor cells with the leukemia-specific ge-
netic alteration in their bone marrow (Feuring-Buske et al.,
1999). A major step toward the development of stem cell-tar-
geted AML therapies would be the identification of key differ-
ences between normal HSCs and the LSC. It has been reported
that the LSC differs from its normal counterpart by the expres-
sion of CD90 or the interleukin-3a receptor, and in a preclinical
NOD/SCID mouse model a diphtheria toxin (DT) human interleu-
kin 3 fusion protein (DT388IL3) was able to selectively kill LSCs in
patients with different subtypes of AML (Blair et al., 1997; Feur-
ing-Buske et al., 2002; Jordan et al., 2000).
The recent reports demonstrating that acute leukemias can
also arise from transformed committed progenitor cells might
improve the chances to define biological differences between
the LSC and the HSC (Huntly et al., 2004; So et al., 2003). How-
ever, leukemic stem cell candidates such as multipotent progen-
itor cells (MPPs) might be difficult to distinguish from normal
HSCs, although first strategies were established in mice to dis-
criminate MPPs from long-term repopulating stem cells by im-
munophenotype (Forsberg et al., 2005; Morrison et al., 1997).
In this report we present experimental evidence that acute mye-
loid leukemia can be propagated by a transformed progenitor,
which differs from normal hematopoietic stem cells by surface
expression of B220 and immunoglobulin heavy chain (IG
DH-JH) rearrangement. We established a murine model of
CALM/AF10 (C/A)-positive acute myeloid leukemia using the
bone marrow transplantation model and retroviral gene transfer
to constitutively express the fusion gene in hematopoietic pro-
genitor cells. The established model well predicted our findings
in patients withC/A-positive AML, who showed a cell population
expressing CD45RA, the human homolog of B220. This human
CD45RA+ cell population displayed IG DH-JH rearrangements,
was positive for the fusion gene as detected by fluorescence in
situ hybridization (FISH), and was able to form CFU-blast colo-
nies in vitro. In these patients the fusion gene is formed by the
translocation t(10;11) (p13;q14), which involves the CALM gene
(associated with clathrin-mediated endocytosis) and AF10 (a
putative transcription factor). This fusion gene is found in a vari-
ety of leukemias, which are all characterized by a very poor prog-
nosis (Dreyling et al., 1998). Of note, the malignant phenotypes
associated with C/A span AML, undifferentiated leukemia, acute
lymphoblastic leukemia, and T cell lymphoma, thus making it
appealing to determine the nature of the leukemic stem cell
candidate(s) in C/A-positive disease. The results of this study
demonstrate in a murine leukemia model that a transformed
progenitor cell population with lymphoid characteristics can
play a key role in propagating C/A-positive AML.364Results
CALM/AF10 induces acute myeloid leukemia in mice
To test the impact of constitutive expression of C/A on murine
hematopoietic development, we employed the murine bone
marrow (BM) transplantation model. The fusion gene was ex-
pressed in a murine stem cell virus (MSCV)-based retroviral con-
struct carrying the C/A cDNA upstream of an internal ribosomal
entry site (IRES)-green fluorescence protein (GFP) cassette that
has been shown to efficiently transduce hematopoietic stem
and progenitor cells (Figures S1A–S1C in the Supplemental
Data available with this article online).
All mice (n = 13) transplanted with highly purified GFP+ C/A
transduced cells (median retroviral transduction efficiency of
5.7, range 1.2%–16.4%) with or without nontransduced helper
cells developed a disease after a median of 110 days posttrans-
plantation (range 46–366) (Figure 1A) and suffered from ca-
chexia, lethargy, and shortness of breath. Detailed analyses of
the hematopoietic compartments showed a more than 10-fold
elevated white blood cell count in the peripheral blood (PB)
of all animals with a median of 4.9 3 107 cells/ml (range 3.2–
8.5 3 107) compared to the GFP control (median 0.48, range
0.32–0.8 3 107) (p < 0.002). Furthermore, mice were anemic,
with a 7.3-fold reduced median red blood cell count of 0.75 3
109 cells (range 0.6–1.253 109) versus 5.53 109 (range 4.8–73
109) in the control mice (p < 0.0001), and suffered from spleno-
megaly (Table 1). Panoptic staining of PB smears and cytospin
preparations of BM and spleen cells revealed an accumulation
of blasts accounting for medians of 32%, 40%, and 39%, re-
spectively, of all cells (Table 1; Figure 1B). The spleen showed
a massive infiltration with myeloid cells (median of 86.9%
Mac1+ cells [range 72.8%–91.1%] versus 12% in the control
[range 7%–26.5%] and 62.5% Gr1+ cells [range 40%–76.2%]
compared to 9.5% in the control [range 7.5%–11.3%]) (Fig-
ure 1B). Histological sections demonstrated infiltration of blasts
in multiple nonhematopoietic organs, including the brain (Fig-
ure 1C). Immunohistochemistry showed positivity of the blasts
for myeloperoxidase (MPO) and chloracetate esterase and
negativity for B220 and CD3, indicating the myeloid nature of
the population (Figure 1D). Taken together, the mice suffered
from acute myeloid leukemia according to the Bethesda pro-
posal for classification of nonlymyphoid and lymphoid hemato-
poietic neoplasms in mice (Kogan et al., 2002; Morse et al.,
2002).
Transplantation of BM cells of leukemic mice into secondary
recipients (n = 22) rapidly induced leukemia with the same char-
acteristics after a median of 15 days (range 14–21 days) post-
transplantation (Figure 1A). Bone marrow aspirations of anes-
thetized primary recipients 8 weeks posttransplantation did
not show any myeloproliferative or lymphoproliferative syn-
drome before the onset of leukemia (n = 5). Analysis of proviral
integration sites demonstrated oligoclonal disease in primary
and secondary mice (Figure S2). Sequencing of the retroviral in-
tegration sites (n = 18) in the diseased mice showed 10 out of 18
sites in or near regions described as common integration sites
(CIS) in the RTCGD database (http://rtcgd.ncifcrf.gov/) (Akagi
et al., 2004). No recurrent integration sites or any association
of the leukemic phenotype with individual proviral integrations
were observed (Table S1). In summary, these data demon-
strated that constitutive expression of CALM/AF10 induced
short-latency AML in transplanted animals.CANCER CELL NOVEMBER 2006
A R T I C L EFigure 1. CALM/AF10 induces transplantable AML
A: Survival curve of mice transplanted with BM cells expressing CALM/AF10 (n = 13, originating from five independent sets of transduction experiments). The
control group was transplanted with BM infected with the GFP empty retrovirus (n = 6). The survival time of secondary recipient mice, transplanted with BM
from diseased primary CALM/AF10 mice or tertiary recipient mice injected with BM from leukemic secondary mice, is indicated. C/A, CALM/AF10.
B: Cytospin preparations from PB, BM, and spleen and immunophenotype of the spleen of a representative leukemic CALM/AF10 mouse in comparison to
a GFP control animal. Cells were stained for the myeloid markers Gr1 and Mac1 and the lymphoid markers B220, CD4, and CD8. The proportion of positive
cells within the GFP+ compartment is indicated; the CD4/CD8 costaining was gated for GFP+ cells. BM, bone marrow; PB, peripheral blood. Scale bar, 10 mm.
C: Histological analysis of diseased CALM/AF10 mice. Blast infiltration in the different organs is shown (brain, intestine, glomerular and tubular areas of the
kidney, sinusoidal and portal areas of the liver, spleen, and lungs) Scale bar, 100 mm; scale bar in inset picture of spleen, 25 mm.
D: Histochemical and immunohistological analysis of the spleen and liver of a diseased CALM/AF10 mouse. Anti-B220 (Da and Db) and anti-CD3 staining
(Dc) of spleen sections and hematoxylin-eosin (Dd), CAE (De), MPO (Df), and anti-CD3 staining (Dg) of liver sections. MPO, myeloperoxidase; CAE, N-acetyl-
chloroacetate esterase. Scale bars, 100 mm in Db–Dg, 25 mm in Da, 50 mm in Dd.CALM/AF10-induced leukemia is propagated by
a transformed B220+, immunoglobulin DH-JH
rearranged progenitor cell
More detailed analyses of the leukemic BM population (GFP+
cells) revealed that, in addition to a majority of cells expressing
myeloid markers (MM) (Mac1+ cells, 82.9% [68.6]; Gr1+ cells,
86.4% [63.7]), there was a small B220+/MM2 cell population
in all animals obtained from five independent sets of experi-
ments, which accounted on average for 6.7% (62.1%) of theCANCER CELL NOVEMBER 2006cells, comparable to the proportion of these cells in control
mice (on average 9.4% 6 3%). An average of 26.0% (68.6)
and 32.5% (613.2) of the BM cells coexpressed B220 with
Mac1 or B220 with Gr1, respectively (n = 4) (B220+/MM+). Highly
purified cells of the B220+/MM2 population had an immature,
blast-like appearance, whereas the B2202/MM+ population in-
cluded blasts as well as terminally differentiated myeloid cells
(Figure 2A). Interestingly, all three subpopulations, including
the cells expressing solely the MMs Mac1 or Gr1, showed DJ365
A R T I C L ETable 1. Hematological parameters in representative experimental mice
Mouse no.
Retroviral
construct
Day of
sacrifice RBCs/ml 3 109 WBCs/ml 3 107
Spleen
weight (mg)
Percent
BM blasts
Percent spleen
blasts
Percent
PB blasts
IgH DJ
rearrangement
1 C/A 10 0.75 3.5 700 30 32 27 ND
2 C/A 78 0.75 5.0 400 40 30 33 +
3 C/A 85 0.6 8.5 250 65 60 61 +
4 C/A 121 0.82 5.2 300 38 38 31 +
5 C/A 85 0.6 4.8 200 78 40 ND +
6 C/A 86 1.25 3.2 400 ND 42 32 +
7a C/A 67 4 2.5 240 32 29 33 +
8a C/A 98 2.65 ND 350 36 ND 28 2
9 GFP 90 6 0.45 150 0 0 0 ND
10 GFP 157 4.8 0.32 200 0 0 0 ND
11 GFP 85 5 0.36 200 0 0 0 ND
12b GFP ND 4.8 0.76 ND 1 0 0 ND
13 b GFP ND 6.4 0.8 ND 0 0 0 ND
14 GFP 90 7 0.5 51 2 0 0 ND
C/A, CALM/AF10; ND, not determined; RBC, red blood cell; WBC, white blood cell; BM, bone marrow; PB, peripheral blood.
aMice were injected with highly purified B220-negative progenitor cells with IgH in germline configuration.
bDetermined by bone marrow aspiration and bleeding of the mouse.rearrangements of the heavy chain of the IgH locus, indicating
that the myeloid population originated from DJ rearranged cells
(Figure 2A). The bulk leukemic population isolated from dis-
eased mice showed unlimited IL3-dependent growth in vitro
and retained its characteristic phenotype with appearance of
the B220+/MM2 as well as the B220+/MM+ and the B2202/
MM+ population (n = 3).
To determine whether the growth potential differed between
the three subpopulations, single cells of the B220+/MM2,
B220+/MM+, and the B2202/MM+ population were sorted
and tested for their proliferative capacity: strikingly, only the
B220+/MM2 population displayed high clonal proliferative po-
tential at the single-cell level, with a mean seeding efficiency
of 29.3% compared to 1% in the other two populations
(Figure 2B). When competitive transcriptional profiling of highly
purified B220+/Mac12 and B2202/Mac1+ cells was performed
by cDNA microarray analysis, 944 genes out of a total of 3643
present genes were differentially expressed between the two
populations. The gene categories, which were significantly
overrepresented in the B220+/Mac12 cells, comprised genes
linked to mitosis and S phase, to response to DNA damage, to
translation, and to DNA repair and replication. In contrast, the
B2202/Mac1+ cells showed overrepresentation of genes be-
longing to the categories cell death, cell communication, and
actin cytoskeleton organization, reflecting the profound differ-
ences in the transcriptome and the proliferative status between
the two populations (http://www.ncbi.nlm.nih.gov/geo/; GEO
accession number GSE5030) (Figure 2C). Importantly, a single
B220+/MM2 cell isolated from leukemic mice could give rise
to the B220+/MM+ and the B2202/MM+ populations in vitro, fur-
ther indicating the hierarchical organization of the leukemic pop-
ulation (Figure 2D). These B2202/MM+ cells were functionally in-
tact myeloid cells and were able to actively phagocytose yeast
cells (Figure 2D). Furthermore, all the B220+/MM+ and the
B2202/MM+ cells derived from a single B220+/Mac12 cell in vitro
displayed identical genomic DJ rearrangements like the original
progenitor (Figure 2E). In conclusion, these data demonstrated
that the B220+/MM2 cells isolated from leukemic mice are able
to give rise to DJ rearranged myeloid cells and have the highest
proliferative potential at the single-cell level compared to the
MM+ subpopulations.366Next it was determined whether highly purified B220+/MM2
cells generated from a single cell in vitro would be able to cause
acute myeloid leukemia in vivo: all animals (n = 3) succumbed
to acute myeloid leukemia after a short latency time of 35 days
posttransplantation when 13 106 cells per mouse were injected.
Thus, the data demonstrated that single B220+/MM2 cells iso-
lated from a leukemic mouse can initiate the leukemia of the
same phenotype as bone marrow cells freshly transduced with
CALM/AF10 retrovirus. In order to test the hypothesis that the
leukemia-propagating cell resides in the B220+/MM2 compart-
ment, we purified the three distinct populations from leukemic
primary recipients and performed limiting dilution transplanta-
tion assays that allowed us to determine the frequency of the leu-
kemia-propagating cell in the three different subpopulations as
previously described (Kroon et al., 1998). Importantly, the fre-
quency of the leukemia-propagating cell was 1 in 36 cells in
the B220+/MM2 population as opposed to 1 in 437 cells in the
B220+/MM+ and 1 in 19,717 cells in the B2202/MM+ compart-
ment. Thus, the frequency of the leukemia-propagating cell
was over 548-fold higher in the B220+/MM2 population com-
pared to the B2202/MM+ population (Figure 3A; Table S2). Strik-
ingly, in our model removal of the B220+ cells from the leukemic
transplant prevented the development of leukemia in mice, in
contrast to the animals, which were transplanted with leukemic
B220+/MM2 cells and died after a median of 34 days posttrans-
plantation (Figure 3B).
To test the possibility that the leukemic stem cells would also
reside in the cell compartment lacking expression of B220 and
the MMs Gr1 and Mac1 (B2202/Gr12/Mac12), bone marrow
cells of leukemic mice were costained with B220-APC, Gr1-
PE, and Mac1-PE: the proportion of this cell population in the
bone marrow was very small, with a median of 0.03% (range
0.01%–0.05%) in four mice tested. Furthermore, only very few
cells expressed the stem cell-associated markers Sca1 and c-
Kit (Figure S3A). To test this population functionally, we highly
purified this subpopulation from leukemic mice and compared
the clonogenic potential of these cells with the B220+/MM2 sub-
population: while the B2202/Gr12/Mac12 population was not
able to form any colonies in vitro, an equal number of B220+/
MM2 cells generated replatable colonies with a frequency of
85 6 13 blast colonies per 1000 cells (data from three miceCANCER CELL NOVEMBER 2006
A R T I C L EFigure 2. Transformed B220+/MM2 cells are IgH DH-JH positive and can generate IgH DH-JH rearranged myeloid cells at the single-cell level
A: Morphology and genomic DH-JH recombination of the immunoglobulin locus in different populations. Wright-Giemsa-stained cytospins of highly purified
B220+/MM2, B220+/MM+, and B2202/MM+ cells and the genomic DH-JH status in different highly purified subpopulations from a representative leukemic
CALM/AF10 mouse. DH-JH status in B220+/Mac12, B220+/Mac1+, B2202/Mac1+, B220+/Gr12, B220+/Gr1+, and B2202/Gr1+ cells is indicated; the myeloid cell
line 32D was used as a DH-JH naive germline control. GL, germline; MM, myeloid marker. Scale bar, 10 mm.
B: Seeding efficiency of the different populations. Single-cell sorting of the three subpopulations, B220+/Mac12, B220+/Mac1+, and B2202/Mac1+, isolated
from a leukemic bulk cell population was performed in 96-well plates, and single-cell growth was determined after culture for 4–5 weeks in IL3-supplemented
medium. The mean seeding efficiency for each population is indicated (n = 3, plotted as mean values 6 SD).
C:Distribution of gene categories significantly overrepresented in highly purified B220+/Mac12 compared to B2202/Mac1+ cells (Ca) and in B2202/Mac1+ ver-
sus B220+/Mac12 cells (Cb). Analysis was performed by DNA microarray-based expression profiling using a chip with 20,172 PCR-amplified, sequence-verified,
gene-specific DNA fragments (LION Biosciences).
D: Phagocytosis by B2202/Mac1+ cells derived from a single-cell-sorted B220+/Mac12 cell. Single-cell-sorted B220+/Mac12 cells were expanded in vitro, and
the B2202/Mac1+ cells generated from these cells were tested for phagocytosis of the yeast S. cerevisiae. A representative picture of a B2202/Mac1+ phago-
cytosing cell is shown. Scale bar, 5 mm.
E: Clonal DH-JH rearrangements in the three subpopulations. B220+/Mac12, B220+/Mac1+, and B2202/Mac1+ cells generated from a single B220+/Mac12
sorted cell all showed the identical clonal DH-JH3 and DH-JH4 biallellic rearrangements. Genomic DNA from splenic cells from a nontransplanted mouse
and the myeloid cell line 32D were used as positive and negative controls for recombination, respectively. B, B220+/Mac12; B/M, B220+/Mac1+;
M, B2202/Mac1+.transplanted initially with independently transduced bone mar-
row; input number 100–1000 cells/dish in both arms). Impor-
tantly, the B2202/Gr12/Mac12 cells did not show leukemic
engraftment into secondary recipients or induced leukemia,
whereas as few as 25 B220+/MM2 cells caused leukemic en-
graftment of the same phenotype as described before (input
number between 25 and 113 cells for the B2202/Gr12/Mac12
cells [n = 5] and an equal number of cells per mouse for
the B220+/MM2 population [n = 5]) (Table S3). Taken together,
the high frequency of the leukemia-propagating cell in theCANCER CELL NOVEMBER 2006B220+/MM2 population, together with its ability to proliferate
and to give rise to a myeloid DJ rearranged cell population, dem-
onstrated that the leukemia-propagating cell resided in the
B220+/Mac12 cell compartment in this murine model.
More detailed analysis of the cell surface phenotype of
the B220+/MM2 cells characterized them as CD43+/AA4.1+/
CD24low-pos/FLT3med/IL-7Rlow-neg, c-Kitlow-neg, CD192, and
Sca12 (Figures 4A and 4B). The cells did not express CD21,
CD23, sIgM, l5, Bp1, or Igb (Figures S4A and S4B), or CD4 or
NK1.1 (data not shown). Transcriptional profiling by RT-PCR367
A R T I C L Eshowed lineage-promiscuous expression of the lymphoid fac-
tors EBF, VpreB, and Rag2 and the MM MPO (Figure 4C;
Figure S4C). Importantly, there was no transcription of Pax5,
which is compatible with the incomplete rearrangement status
at the IgH locus (data not shown) and the CD19 negativity of
the cells (Figure 4B). In the B220+/Mac1+ and in the B2202/
Mac1+ cells, transcripts for the M-CSF receptor became detect-
able, whereas transcription for EBF was downregulated. There
was no detectable transcription of Gata3, Zfpn1a3 (Aiolos)
(Figure 4C), or mb1 and only low expression of l5 transcripts
(Figure S4C). In addition, we could not detect rearrangements
of the TCRg receptor, specifically Vg 1.1-Jg4, Vg 2/4-Jg1, or
Vg 5/7-Jg1 by PCR (data not shown). The surface marker ex-
pression as well as the transcription factor expression profile
collectively defined the B220+/MM2 population as a lymphoid
progenitor (Figure S5).
In an effort to determine whether an earlier B220-negative cell
could be transformed by the CALM/AF10 fusion gene, we next
analyzed whether transduction of CALM/AF10 into highly
purified B220-negative cells with IgH germline configuration
Figure 3. Frequency of leukemia-propagating cells
A: Determination of the frequency of leukemia-propagating cells. Cohorts
of secondary mice were injected with highly purified B220+/Mac12, B220+/
Mac1+, and B2202/Mac1+ populations from primary leukemic mice in a lim-
iting dilution assay. The frequency of leukemia-propagating cells in each
population is indicated. Details of cell numbers, number of mice per arm,
and the median latency of disease are described in Table S2.
B: Survival of mice transplanted with leukemic BM depleted of B220+ cells
(B2202/Mac1+cells, n = 11; 50 cells [n = 4], 500 cells [n = 4], and 5000 cells
[n = 3] isolated from the primary leukemic population). In comparison the sur-
vival of mice (n = 12) transplanted with B220+/Mac12 cells with the same
range of cell numbers (50 [n = 4], 500 [n = 4]), and 5000 cells [n = 4]) is shown.368resulted in the induction of AML of the same phenotype as de-
scribed for the transduction of unfractionated bone marrow:
two of two animals tested developed acute myeloid leukemia af-
ter transplantation of 1–2 3 105 B220-negative cells proven to
have IgH germline configuration by PCR before injection, indi-
cating that early B220-negative progenitors with IgH germline
configuration can acquire leukemogenic potential after CALM/
AF10 transduction. However, whereas one of the AML cases
showed B220+ cells with IgH DJ rearrangement as described
before, the other case did not display a B220+ subpopulation.
In addition, the leukemic bulk had a germline IgH configuration,
a phenotype not observed in the transplantation assays using
5-FU-mobilized unfractioned bone marrow for viral infection
(Figure S3B and Table 1). In contrast to early B2202 progenitors,
murine cell populations comprising pro-B cells (B220+/CD43+/
CD252; input number 2 3 106 cells per mouse; transduction
efficiency, 10%) and pre-B cells (B220+/CD43+/CD25+ cells;
input number 2 3 105 cells per mouse; transduction efficiency,
2%) did not acquire in vivo repopulating activity with no short-
or long-term engraftment in lethally irradiated mice 4 or 8 weeks
posttransplantation, respectively (data not shown).
To examine whether our findings in the murine CALM/AF10
leukemia model parallel characteristics of human CALM/AF10-
positive AML, patient samples were analyzed for IGDH-JH rear-
rangement status and the presence of a CD45RA (the human
homolog to B220) population. In addition, we further character-
ized the CD45RA+ population by performing CFU-blast colony
assays in vitro and FISH analysis for the presence of the
CALM/AF10 fusion gene. Table S4 summarizes the characteris-
tics of patients diagnosed with AML or in one case with acute
undifferentiated leukemia (AUL); two of the nine patients were
children, six of nine patients had additional genetic alterations
to the CALM/AF10 t(10;11) translocation. Treatment consisted
mainly of chemotherapy with high-dose Ara-C and anthracy-
clines, and outcome was dismal in all the patients with longer
follow-up. Multiplex PCR and clonality analysis by GeneScan-
ning techniques showed that seven out of nine AML samples
demonstrated clonal IG DH-JH rearrangements (Table 2 and
Figure 5A). We could also detect immature TCRd (Dd2,Vd2)
and TCRb (TCRb DJ) as well as TCRg (Vg10) rearrangements
in six out of six patients tested (Table 2).
In all three patients tested, a substantial proportion of
CD45RA+ cells could be detected, ranging from 50.6% to
99.8% of bone marrow cells. In two of the three patients, the
CD45RA-positive population coexpressed CD34. In all the pa-
tients tested, the CD34+/CD45RA+ cells harbored the CALM/
AF10 fusion gene as detected by FISH analysis (Figure 5Bb)
(Table 3). Furthermore, CD34+/CD45RA+/CD10+ cells, corre-
sponding to the stage of early human lymphoid progenitors
(Haddad et al., 2004), were also positive for the fusion gene
(data not shown). The involvement of the CD45RA population
in the malignant transformation process was further supported
by the observation that the CD45RA population generated my-
eloid CFU-blasts (Table 3) in vitro, which showed the identical
IG DH-JH rearrangement status at a single-colony level as de-
tected in the myeloid bulk population (Figure 5C). To test
whether early CD34+/CD45RA2 cells could be positive for the
CALM/AF10 fusion gene, we highly purified CD34+/CD45RA2/
lineage marker (lin)-negative (lin: CD382/CD192/CD102) cells
of one patient with C/A-positive AML. Notably, the fusion gene
could be detected in the majority of cells (92%) in this primitiveCANCER CELL NOVEMBER 2006
A R T I C L EFigure 4. Leukemic B220+/Mac12 cells express lymphoid markers
A: Expression of B cell-associated markers on leukemic B220+/Mac12 cells: flow cytometric analysis after staining with various markers as indicated.
B: Expression of early and late markers on leukemic B220+/Mac12 cells propagated in vitro for Sca1 (Bb) and c-Kit (Bc) or CD19 (Be); Ba and Bd are controls
as indicated.
C: RT-PCR analysis of lineage associated genes. B220+/MM2, B220+/MM+, and B2202/MM+ cells clonally generated from a single B220+/Mac12 cell were an-
alyzed for the expression of genes associated with different hematopoietic lineages as indicated. B220+ sorted cells from the spleen, Mac1+ sorted cells from
the bone marrow, and unsorted BM cells (all populations isolated from a nontransplanted control mouse) were used as controls for lymphoid and myeloid
transcripts, respectively. MPO, myeloperoxidase; EBF, early B cell factor; HPRT, hypoxanthine phosphoribosyl transferase; B220+/MM2, B220+/Mac12 cells;
B220+/MM+, B220+/Mac1+ cells; and B2202/MM+, B2202/Mac1+ cells.cell compartment (Figure 5Ba, patient number 9), indicating the
involvement of early CD45RA-negative cells in the transforma-
tion process in this patient. In summary, these findings indicate
that patients with CALM/AF10-positive AML are characterized
by IG DH-JH rearrangements of their leukemic blasts and
a CD45RA-positive population, which is positive for the leuke-
mia-specific fusion gene and is able to generate myeloid blast
colonies with the clonal IG DH-JH rearrangement ex vivo,
reminiscent of several characteristics of murine CALM/AF10-
induced AML in transplanted mice.
Discussion
Leukemias are considered to originate from a rare subset of
transformed cells, which are able to initiate and maintain theCANCER CELL NOVEMBER 2006disease. In particular, studies in patients with acute myeloid leu-
kemia have shown that the transformation process involves
early hematopoietic progenitor cells characterized by expres-
sion of CD34 and lack of CD38 and the different lineage markers
(Blair et al., 1998; Dick, 2005). The concept that hematopoietic
stem cells (HSCs) are a key target of leukemic transformation
was further supported by murine models, which demonstrated
that HSCs could acquire leukemic stem cell properties by forced
expression of appropriate oncogenes, recurrently found in pa-
tients with AML (Huntly and Gilliland, 2005; Reya et al., 2001).
Furthermore, inactivation of certain transcription factors such
as JunB caused leukemia only when the targeted deletion
took place in the HSC compartment and not in the more dif-
ferentiated cell pool (Passegue´ et al., 2004). However, more
recent data have provided in vivo evidence that also more369
A R T I C L ETable 2. IgH DJ and TCR rearrangements in CALM/AF10 AML patients
Patient
no. Type
IgH DJ rearrangements TCR rearrangements
IgH DJ IgH DJ sequences TCRg TCRd TCRb DJ
1 AML M0 monoclonal
DH3
D39/ATTTTGACTGGTTATTATAAC*GT*CTGGTACTT
CGATCTCTGGGGCCT/JH2
monoclonal Vg10 Dd2 biallelic polyclonal
2 AML M2 monoclonal
biallelic
DH2 DH6
D2-15/TGGTAGCTGCTACTC*TT*TACGGTATGGAC
GTCTGGGGCCA/JH6B D6-13/GGGTATAGCAG
C*GGCTACAAGGGT*ACTACTGGGGCCA/JH4B
monoclonal Vg10 Vd2 monoclonal D1
3 AML M1 polyclonal
DH1–7
— polyclonal Dd2/Dd3 biallelic polyclonal
4 AUL monoclonal
DH1
DH1-26/TATAGTGGGAGCTACT*GTG*CTACTGG
GGCCA/JH4B
monoclonal Vg1-8
and Vg10-11
Dd2 monoclonal TCRb
DJ and TCRb JA
5 AML M1 monoclonal
DH7
ND polyclonal Dd2 biallelic polyclonal
6 AML M1 monoclonal
DH7
ND monoclonal Vg10-11 Dd2 biallelic monoclonal
TCRb DJ
7 AML M1 monoclonal
DH6
DH6-6/TATAGCAGCTCGT*TGT*ACTACTTTGACT
ACTGGGGCCA/JH4B
ND ND ND
8 AML monoclonal
DH7
DH7-27/TAACCACTGGGGAC*CTCCCGGG*
CTTTGACTACGGGGCCA/JH4B
ND ND ND
9 AML M5a polyclonal
DH1-7
— ND ND ND
ND, not determined.differentiated cells can acquire properties of leukemic stem
cells: in a murine bone marrow transplantation model, retrovir-
ally driven expression of the MLL-GAS7 fusion gene induced370acute leukemias with myeloid, lymphoid, or mixed phenotype.
Immunophenotyping, transcriptional profiling, and the ability of
the LSC to induce three distinct leukemia subtypes indicatedFigure 5. CALM/AF10-positive human AML samples show IgH DH-JH rearrangements and express CD45RA(B220)
A: GeneScanning analysis of IgH DH-JH rearrangements in nine cases of human CALM/AF10-positive AML using bone marrow of the leukemic patients with
>80% myeloid blasts and polyclonal nonleukemic control cells. GeneScanning demonstrated a clonal IgH DH-JH rearrangement in seven out of nine cases.
Unspecific background peaks resulting from annealing to nonrearranged alleles in the reactions are indicated with an asterisk.
B: Detection of the CALM/AF10 rearrangement in flow-sorted patient cells. Ba:A representative CD34+/CD45RA2/lin2 cell with the CALM/AF10 fusion, showing
a normal AF10 (red) and a normal CALM (green) locus as well as two red/green signals, indicating the two reciprocal fusion genes (arrowheads) (92% of the cells
were positive for the fusion gene; one representative CALM/AF10-negative cell of the same compartment is shown in Bc) (patient number 9). Bb: A represen-
tative CD34+/CD45RA+ cell carrying the CALM/AF10 fusions, showing the same signal pattern as inBa (fusion signals are indicated by arrowheads) (patient num-
ber 7). Bc: A CD34+/CD45RA2/lin2 cell without CALM/AF10 fusion showing two normal AF10 (red) and two normal CALM (green) signals (patient number 9).
C: Myeloid blast colony formation in methylcellulose of CD45RA+ cells of a representative human AML patient (patient 7, magnification 1003). Lower panel
shows the clonal IgH DJ rearrangement peak from a singly isolated myeloid blast colony analyzed by GeneScan. The rearrangement was identical to the re-
arrangements detected in the leukemic bulk of the patient (Figure 5A).CANCER CELL NOVEMBER 2006
A R T I C L ETable 3. Proportion of CD45RA-positive cells and CFU-blast frequency of C/A-positive AML patients
Patient no.
CD34+/
CD45RA+
Overall
CD45RA+
CD34+/
CD45RA2/lin2b
Positivity for CALM/AF10c
CFU-blast
frequencya
IgH DJ of CFU-blast
coloniesCD34+/CD45RA+ CD34+/CD45RA2/lin2
3 94.52% 98.59% 0.13% + ND 92 6 14 NA
7 96.21% 99.8% 0.01% + ND 12 6 3 monoclonal DH6
9 1.68% 50.6% 33.07% ND + ND ND
ND, not determined; NA, not applicable.
aPer 106 CD45RA+ bone marrow cells isolated from C/A AML patients (0.2–2 3 105 cells plated per dish).
bLineage markers comprised CD38, CD19, and CD10.
cAs determined by CALM- and AF10-specific FISH probes.that the fusion gene targeted a multipotential progenitor in this
murine model (So et al., 2003). In addition, retroviral expression
of the MLL-ENL or MOZ-TIF2 fusion gene in murine myeloid
committed progenitor cells clearly demonstrated that commit-
ted progenitor cells can function as leukemic stem cells in these
models and that transformation of HSC is not mandatory for the
development and maintenance of acute leukemia (Cozzio et al.,
2003; Huntly et al., 2004). The murine data presented here now
provide evidence that a progenitor cell with lymphoid character-
istics can propagate acute myeloid leukemia. Detailed charac-
terization of the leukemic stem cell showed that the cells ex-
pressed B220, CD43, AA4.1, and CD24 but lacked expression
of MMs as well as Sca1. Importantly, transcriptional profiling
demonstrated a lineage-promiscuous expression of lymphoid
factors such as EBF, VpreB, and Rag2 (Busslinger et al., 2000)
with progressive downregulation following differentiation into
the B220+/Mac12 and the B2202/Mac1+ cells together with
the MM MPO. Of note, we did not detect transcription of
Pax5, which is compatible with our finding that the B220+ cells
had an incomplete rearrangement status at the IG DH-JH locus
and did not express CD19. Even though this progenitor showed
characteristics of the early B lineage, the classification of this
CALM/AF10 leukemia-propagating cell according to the differ-
ent B cell classification systems remains difficult because of
its leukemogenic characteristics and the potential impact of
the fusion gene on its cell surface phenotype and transcriptional
network. The phenotype we observed differed from the B220+/
CD19+ cell stage, which is associated with Pax5 positivity and
the entire commitment to the B cell lineage (Hardy, 2003), but
also from the profile of the earliest lymphoid progenitor, the
common lymphoid progenitor (CLP), which lacks expression
of B220 (Kondo et al., 1997).
In our model, a single transformed Pax5-negative progenitor
with lymphoid characteristics was able to generate myeloid
cells with IgH immunoglobulin rearrangements. Interestingly,
Pax52/2 B cell progenitors show lineage-promiscuous tran-
scription of B-lymphoid and myeloid genes, display a remarkable
multilineage potential in vitro, and are able to be directed into the
myeloid lineage (Heavey et al., 2003; Schaniel et al., 2002). In ad-
dition, the latent myeloid differentiation capacity of the CLP,
which does not express Pax5 yet, has become obvious due to
the observation that it can be redirected to the myeloid lineage
by retrovirally induced IL-2Rb chain or GM-CSF receptor
expression (Kondo et al., 2000). Thus, one intriguing possibility
is that CALM/AF10 instructed myeloid development of an early
Pax5-negative lymphoid progenitor in our model. This com-
mitment into the myeloid pathway was irreversible in the C/A
model, as highly purified B220+/Mac12 cells were not able toCANCER CELL NOVEMBER 2006differentiate along the B lineage pathway in vitro on stromal
OP9 feeders in lymphoid growth medium (data not shown).
The scenario that expression of C/A directs the lineage
choice of Pax5-negative lymphoid progenitors is only one po-
tential explanation for the myeloid phenotype of the leukemia.
We cannot exclude that the fusion gene instructed myeloid lin-
eage decision at the later stage of Pax5-positive cells, as it was
recently shown that the myeloid transcription factors C/EBPa
and C/EBPb could convert Pax5-positive B cells into macro-
phages by downregulation of Pax5 expression and upregula-
tion of myeloid genes (Xie et al., 2004). However, we could
not observe any significant downregulation of Pax-5 expression
following CALM/AF10 expression for 48 hr in the in vitro culti-
vated murine pro-B cell line Ba/F3 or primary murine fetal
pre-B cell lines by real-time quantitative PCR and did not ob-
serve repopulating ability of murine pro-B or pre-B cells in le-
thally irradiated mice after transduction with CALM/AF10
(data not shown).
Another important scenario would be that the CALM/AF10 fu-
sion gene targets a rare and early B220-negative progenitor with
IgH germline configuration and activates lymphoid develop-
mental programs in these cells, resulting in a B220+/MM2 IgH
rearranged cell population with high leukemia-propagating po-
tential as described in the murine model. Indeed, highly purified
B220-negative progenitor cells with IgH germline configuration
acquired leukemogenic properties in vivo in two independent
experiments after infection with the CALM/AF10 retrovirus, indi-
cating that an early progenitor cell can be transformed by the fu-
sion gene. Interestingly, one of the mice developed an AML that
lacked a B220+ population and displayed an IgH germline con-
figuration, which was never observed when unfractionated bone
marrow was infected with the CALM/AF10 retrovirus and trans-
planted into recipients. One explanation for this might be that
C/A can target IgH rearranged B220+ lymphoid progenitors, giv-
ing rise to AML with the consistent phenotype of a B220+ trans-
formed progenitor population, as well as early B2202 progeni-
tors with IgH germline configuration, resulting in AML with or
without the B220+ cell population.
Importantly, the experiments performed in this study do not
rule out the other possibility, that the CALM/AF10 fusion gene
had an instructive effect on myeloid progenitors, initiating a lym-
phoid-specific program in these cells. In this scenario a myeloid
cell would acquire lymphoid characteristics as a result of trans-
formation by an appropriate oncogene. Another possibility is
that C/A directly transformed a rare cell subset of B/macro-
phage progenitors, which was identified in fetal liver but also
in adult bone marrow (Lacaud et al., 1998; Montecino-Rodri-
guez et al., 2001). However, this cell was described to be371
A R T I C L ECD19/Pax5 positive and negative for CD45R/B220, a phenotype
different than the phenotype of the LSC described here.
Of note, these different scenarios would result in the develop-
ment of AML with a B220+/MM-negative cell population with
a very high frequency of leukemia repopulating cells, which
would be accessible to an antibody-based B220 depletion. In-
deed antibody-mediated depletion of the B220+/MM2 cells
from leukemic transplants efficiently prevented leukemic devel-
opment in mice, underlining the key role of this population for
disease propagation. One implication of our findings is that in
a subset of AML the leukemia-propagating cell might show a dis-
tinct cell surface and transcriptional phenotype, setting it apart
from the leukemic myeloid bulk population, but also from the
normal stem cell pool. In particular, the expression of lymphoid
antigens would allow to discriminate this cell from the normal he-
matopoietic stem cells, which would facilitate the development
of treatment strategies using the lymphoid surface antigens to
target the leukemia-propagating cell but to spare the normal
stem cell (Passegue´ et al., 2003). As illustrated in the murine
CALM/AF10 leukemia model, such a strategy would have thera-
peutic potential. Depletion of the B220+ transformed progenitor
cells would fail to eradicate the malignant clone, if a rare leuke-
mic B220-negative progenitor cell population existed, which
gives rise to the B220+/MM2 population described. But even in
this scenario, diminishing the B220-positive leukemia-propagat-
ing cells would promise clinical benefit, as mice transplanted
with B220-depleted bone marrow failed to develop leukemia
up to an observation time of 100 days, compared to rapid devel-
opment of AML in mice transplanted with B220+ transformed
progenitors.
Recently, substantial progress has been made to characterize
very early stages in human B cell development (Haddad et al.,
2004; Hou et al., 2005; LeBien, 2000; Ryan et al., 1997). These
reports have shown that similar to the murine system these early
human progenitors express the B220 human homolog CD45RA,
as well as CD34 and CD10, but lack CD19 and Pax5 expression.
In an effort to determine potential similarities between the mu-
rine CALM/AF10 AML and human disease, we analyzed nine pa-
tients with CALM/AF10-positive AML. Interestingly, the cases
tested showed a CD45RA population with coexpression of
CD34 in two of three patients. Furthermore, in seven out of
nine patients tested, clonal IgH immunoglobulin rearrangements
could be detected in the myeloid bulk. The leukemic nature of
the CD45RA population in these cases was indicated by the
presence of the fusion gene, its clonal IgH rearrangement, and
its ability to form CFU-blast colonies ex vivo. Interestingly, in
the CD34+/CD45RA2/lin2 progenitor compartment of one pa-
tient we detected a mosaic of cells carrying the fusion gene or
showing normal signal pattern by FISH, indicating that this cell
compartment might be involved in the malignant transformation
process.
In addition to IgH rearrangements, six of six patients were also
positive for clonal rearrangements of the T cell receptor (TCR).
These observations are in line with reports associating the
CALM/AF10 fusion gene with T-ALL, in particular with T-ALLs
expressing the g/d TCR (Asnafi et al., 2003). In the murine model
the constitutive expression of CALM/AF10 failed to induce T cell
leukemia, and the observed myeloid leukemias did not show the
TCRg rearrangements that were analyzed (Vg 1.1-Jg4, Vg 2/4-
Jg1, or Vg 5/7-Jg1). This could be attributable to various factors
predisposing the murine model to leukemias of the myeloid372lineage, such as the cell population initially used for retroviral in-
fection; the in vitro culture conditions with IL3, IL6, and SCF
stimulation before transplantation; or the level of expression of
the fusion gene in the murine system compared to human dis-
ease. However, real-time PCR quantification of CALM/AF10
transcripts showed low CALM/AF10 expression in both the mu-
rine and human myeloid bulk (data not shown). Insertional muta-
genesis was identified as an important factor in murine leukemo-
genesis (Akagi et al., 2004; Suzuki et al., 2002) and might explain
the predisposition to AML development in the CALM/AF10
model: in an analysis of the proviral integration sites in leukemic
mice, 10 of 18 detected sites were described before as common
integration sites or transposon-tagged cancer genes according
to the Retroviral Tagged Cancer Gene Database (RTCGD; http://
RTCGD.ncifcrf.gov/) (Akagi et al., 2004). However, there were no
recurrent insertion sites or a correlation of the integrations with
the consistent phenotype of the leukemias in this model. As de-
scribed for humanCALM/AF10-positive T-ALLs (Dik et al., 2005;
Soulier et al., 2005), the murine AML cases also displayed aber-
rant expression ofHoxA7 andMeis1 (unpublished data); further-
more, we also observed deregulation of HOX genes in patients
with CALM/AF10-positive AML (unpublished data). This indi-
cates that deregulation of this transcription factor family is a
common characteristic of CALM/AF10 leukemias independent
of the phenotype.
In summary, this murine leukemia model demonstrates that
a progenitor cell with lymphoid characteristics and a phenotype
that differs from that of normal hematopoietic stem cells and the
leukemic myeloid bulk, is able to propagate AML. These data
provide a rationale for the development of therapeutic strategies
targeting the leukemia-propagating stem cell without harming
the normal stem cell pool and raise the hope that such innova-
tive concepts may improve treatment outcome in a subgroup
of patients with AML in the future.
Experimental procedures
Retroviral transduction of primary bone marrow cells
and BM transplantation
Breeding and maintenance of the mice were conducted as described previ-
ously (Rawat et al., 2004). Production of high-titer helper-free retrovirus was
carried out following standard procedures by using the ecotropic packaging
cell line GP+E86 (Schessl et al., 2005). Lethally irradiated (0.80 Gy) mice were
transplanted with either highly purified EGFP+ cells alone (4 3 105 cells per
mouse) (FACSVantage, Becton Dickinson) or with a mixture of transduced
and nontransduced cells (on average 1.763 105 transduced cells with 1.93
105 nontransduced cells per mouse). Lethally irradiated secondary and
tertiary recipients were injected with 1 3 106 BM cells from a primary and
secondary diseased mouse, respectively, with an equal number of nontrans-
duced cells from a syngenic disease-free mouse bone marrow for radiopro-
tection. Both animal and human studies were approved by the Ethics
Committee of Ludwig Maximilians University and abided by the tenets of
the revised World Medical Association Declaration of Helsinki (http://www.
wma.net/e/policy/b3.htm).
In order to determine the frequency of leukemia-propagating cells, B220+/
Mac12, B220+/Mac1+, and B2202/Mac1+ cells were isolated and highly pu-
rified from the BM of a leukemic primary mouse. The sort purity of these cells
was analyzed with the FACSCalibur and determined to be over 98%. In each
cohort 10-fold serial dilutions of these cells were injected intravenously (50
cells to 53 105 cells per mouse cohort) into lethally irradiated secondary re-
cipient mice. Carrier cells (13 106) (nontransduced BM from a syngenic dis-
ease-free mouse) were added to each sample for radioprotection. Diseased
mice were sacrificed and assessed for leukemia development. Mice that did
not develop disease within 20 weeks posttransplantation were sacrificed andCANCER CELL NOVEMBER 2006
A R T I C L Etested for engraftment. The frequency of leukemia-propagating cells was
calculated using Poisson statistics using the L-Calc Limiting dilution analysis
software (Version 1.1 StemSoft Inc., Vancouver, Canada) (Buske et al., 2002).
Patient samples
BM samples from adult patients diagnosed with AML were analyzed. The di-
agnosis of AML was performed according to the French-American-British
criteria and the World Health Organization classification (Bennett et al.,
1985; Harris et al., 1995). Cytomorphology, cytochemistry, cytogenetics,
and molecular genetics were applied in all cases as described below. The
clinical features of patients are provided in Table S4. The study abided by
the rules of the local internal review board and the tenets of the revised
Helsinki protocol (http://www.wma.net/e/policy/b3.htm).
Sorting of cells from human AML patient samples
Frozen mononuclear peripheral blood or bone marrow cells from patients
with AML were rapidly thawed and were washed twice in IMDM with 10%
FBS, resuspended in PBS, and stained with various antibodies. For lineage
depletion experiments, immunostaining was done with FITC-labeled anti-hu-
man CD34 (Beckman Coulter, Marseille, France) and PE-labeled anti-human
CD38, PE-labeled anti-human CD19, PE-labeled anti-human CD10, and PE-
labeled anti-human CD45RA (all from BD Pharmingen, Heidelberg, Ger-
many). Cells were incubated with appropriate antibodies for 20 min on ice
and washed with cold PBS prior to sorting. The trial was approved by the re-
sponsible local ethics committees, and all patients gave written informed
consent according to the Helsinki Declaration.
FISH
Dual Colour Dual Fusion (DCDF) probes were developed with bacterial artifi-
cial chromosome (BAC) clones RP11-418C1 for the 50-AF10 region (Texas
Red; red in Figure 5B), RP11-249M6 for the 30-AF10 region (red), RP11-
12D16 (FITC, green) for the 50-CALM region, and RP11-90K17 (green) for
the 30-CALM region (kindly provided by Dr. Mariano Rocchi, Bari). BAC
DNA preparation, labeling, and FISH were performed as described (Cre-
scenzi et al., 2004). Normal nuclei display a two-red and two-green (2R2G)
hybridization pattern, whereas nuclei carrying the translocation display
a one-red, one-green, twored/green fusion (1R1G2F) pattern. Other hybrid-
ization patterns, e.g., 1R1G1F (found in 0.5%–2% of nuclei) or 1R1G3F
(found in 0.5%–1% of nuclei), were interpreted as technical artifacts.
The cells were directly sorted onto aminoalkylsilane-coated slides (Silane-
Prep Slides, Sigma, Germany) with or without preloading of 15 ml 3% bovine
serum albumin solution in PBS and fixed in 1:3 acetic acid-methanol fixative.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures, five
supplemental figures, and five supplemental tables and can be found with
this article online at http://www.cancercell.org/cgi/content/full/10/5/363/
DC1/.
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